The purpose of this study was to evaluate the hemodynamic safety and efficacy of a new air-filled biocompatible echo contrast agent. Method: Blood pressure (BP), heart rate (HR) and transesophageal echoes were monitored in six closed chest dogs; while cardiac output (CO), pulmonary artery (PA), pulmonary artery wedge (PAW) and arterial pressures were continuously monitored in one dog; and myocardial perfusion was imaged in two open chest dogs before, during, and after coronary occlusion with harmonic Acoustic Densitometry (AD) and Power Angio (HP5500) recordings. Serial contrast injections of air-filled biSpheres (Point Biomedical) ranging from 0.5 ml (fluid suspension) to 24 ml (cumulative dose of up to 48 ml) were made in peripheral veins. Results: Left heart enhancement for 60 minutes or longer was easily seen with all 0.5 ml or larger injections. The hemodynamic response was measured as the mean change (Δ) from the pre-injection to post injection values. The hemodynamic changes were: Δ systolic BP 1.47±8.09, Δ diastolic BP 2.06±0.83mmHg, Δ HR 1.06±4.52, and Δ CO 0.22±0.44L/min. (P=NS) Myocardial AD intensity was 35± 5 units in normal myocardium and 10± 5 units in ischemic myocardium (p<.01). Power angio intensity was even brighter in normal and darker in ischemic areas. Conclusions: Air-filled biSphere contrast agents provide reliable and long-lasting left heart opacification and do not alter hemodynamics at individual doses of 0.5-24 ml and cumulative doses of 48 ml. These air-filled biSpheres provide intense myocardial opacification in both harmonic back scatter and Power Angio imaging which easily distinguishes normal from ischemic myocardium. These biologically compatible, long-lasting contrast agents should provide useful physiologic information in health and disease.
|Original language||English (US)|
|Journal||Journal of Investigative Medicine|
|State||Published - Feb 1999|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)